PCOS Gets a New Name — And It Changes Everything for 170 Million Women

For decades, millions of women were told they had a disease of cysts. They searched for cysts on scans, worried about cysts, and were dismissed when no cysts were found, even as they battled irregular periods, insulin resistance, unexplained weight gain, and crushing fatigue. The name was wrong. And finally, medicine has admitted it.

On May 12, 2026, a landmark global consensus published in The Lancet officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS), a name that, for the first time, actually reflects what the condition really is.

"It was heartbreaking to see the delayed diagnosis, limited awareness, and inadequate care afforded to those affected by this neglected condition." — Prof. Helena Teede, Monash University

The old name was never accurate. Research has since shown there is no meaningful increase in abnormal ovarian cysts in those affected. What PMOS actually involves is a complex interplay of hormonal fluctuations, metabolic dysfunction, elevated androgen levels, and risks of type 2 diabetes and cardiovascular disease — none of which the old name hinted at.

The name change, backed by 56 patient and professional organisations including the Endocrine Society, followed a 14-year global process involving over 22,000 survey responses from patients and clinicians across all world regions. The goal was not just semantics; it was survival. An estimated 70% of women with the condition remain undiagnosed, partly because both patients and doctors fixate on cysts that were never the real story.

A three-year transition period begins now, with full implementation expected in the 2028 International Guideline update. For the 1 in 8 women living with this condition, the message is clear: you were never just a cyst. You were always so much more.